Our findings suggest that ROPI not only functions as a canonical DRD2 agonist but also has pleiotropic DRD2‐independent effects, offering a novel avenue for treatment strategies that target multiple pathways involved in ALS pathology. The gene discussed is DRD2; the disease is amyotrophic lateral sclerosis.